key: cord-0997348-ip71xtzq
authors: Savarraj, J. P.; Park, E. S.; Copo, G.; Hinds, S.; Morales, D.; Ahnstedt, H.; Assing, A.; Juneja, S.; Kim, E.; Cho, S.-M.; Gusdon, A.; Dash, P.; McCullough, L.; Choi, A.
title: Markers of brain and endothelial Injury and inflammation are acutely and sex specifically regulated in SARS-CoV-2 infection
date: 2021-05-27
journal: nan
DOI: 10.1101/2021.05.25.21257353
sha: 073bbcdc75c71538e864885b800758e21be06d75
doc_id: 997348
cord_uid: ip71xtzq

Objective: To investigate brain injury markers (BIM), endothelial injury markers (EIM) and cytokine/chemokine (CC) markers of systemic inflammation in coronavirus disease 2019 (COVID-19) and across sex. Methods: Plasma samples from 57 subjects at <48 hours of COVID 19 hospitalization, 14 subjects at 3 months of COVID 19 hospitalization and 20 matched controls were interrogated for the levels of six BIMs, including GFAP, S100B, Syndecan1, UCHLI, MAP2 and NSE, two EIMs, including sICAM1 and sVCAM1 and thirty eight CCs. Statistical and bioinformatics methods were used to measure differences in the marker profiles across (a) COVID 19 vs controls and (b) men vs women. Results: Three BIMs: MAP2, NSE and S100B, two EIMs: sICAM1 and sVCAM1 and seven CCs: GRO IL10, sCD40L, IP10, IL1Ra, MCP1 and TNFa; were significantly (p<0.05) elevated in the COVID 19 cohort compared to controls. Two CCs: MDC and MIP1a; were significantly lower in the COVID-19 cohort. Bioinformatics analysis reveal a stronger positive association between BIM/CC/EIMs in the COVID-19 cohort. Analysis across sex revealed that several BIMs and CCs including NSE, IL10, IL15 and IL8 were significantly (p<0.05) higher in men compared to women. Men also expressed a more robust BIM/ EIM/CC association profile compared to women. At 3 months, BIMs and CCs were not significantly different in the COVID-19 cohort compared to controls. Conclusion: The acute elevation of BIMs, CCs, and EIMs and the robust associations among them at COVID-19 hospitalization suggest that brain injury is mediated by endotheliopathy and inflammation. Higher BIM and inflammatory markers in men additionally suggest that men are more susceptible to the risk compared to women.

Introduction: Neurologic complications after COVID-19 have been reported in both the acute and chronic period 1, 2 . Neurologic manifestations including ischemic and hemorrhagic stroke (which are direct acute medical complications of COVID-19) have been reported. But neurologic manifestations without clear etiology including encephalopathy, pain, chronic fatigue and cognitive dysfunction have also been reported demonstrating the wide impact of COVID-19 on the nervous system [3] [4] [5] [6] [7] [8] .

Human coronaviruses (HCoV) are neuroinvasive and neurotropic by nature and may contribute to both short-and long-term neurological disorders [9] [10] [11] . SARS-CoV (of the SARS epidemic in early 2000s) has been shown to affect the CNS 12 and viral strains have been identified in post-mortem human brain tissue 12, 13 . Our understanding of the effect of COVID-19 on brain injury is only beginning to be developed. COVID-19 triggers multiple pathological mechanisms -including an acute inflammatory response and endotheliopathy -and the relationship of these mechanisms with brain injury is unclear.

Further, it is not known whether the BIMs continue to be elevated in the long-term after COVID-19.

Sex differences in COVID-19 are prominent, with men having higher hospitalization rates and mortality rates-an effect seen globally 14, 15 . Sex differences in the immune responses have been shown to underlie the increase in mortality seen in men during the acute disease course 16, 17 . It is uncertain whether the increase in peripheral inflammation seen in accompanied by an increase in brain injury markers as well.

We investigated brain injury in COVID-19 patients by measuring brain injury markers (BIMs) in the acute (<48h) and chronic phase (3 months) after hospitalization. Several

BIMs have been established in neurologic diseases and have been reported as All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101/2021.05.25.21257353 doi: medRxiv preprint surrogate markers of neuronal and astrocytic injury in non-neurological diseases like HIV [18] [19] [20] , cardiac arrest [21] [22] [23] and sepsis 24 as well. Among them, we measured six validated BIMs including glial fibrillary acidic protein (GFAP), neuron specific enolase (NSE), S100B, ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1), Syndecan-1 and microtubule-associated protein 2 (MAP 2) in plasma drawn from hospitalized COVID-19 subjects and matched controls. In addition to BIMs, we measured two endothelial injury markers (EIMs) (including Intercellular Adhesion Molecule 1 (ICAM- 1) and Vascular Cell Adhesion Molecule 1 (VCAM-1)) and several cytokine/chemokine markers (CCs) of systemic inflammation to investigate if endothelial injury and inflammation are associated with BIMs. The levels of the markers were measured by ELISA and multiplex assays, and the association between COVID-19 and controls were characterized using statistical and bioinformatics approaches. The differences in the levels of markers between men and women were investigated.

Study population and patient inclusion and exclusion criteria: This is a prospective study of COVID- 19 Samples: Blood was drawn by venipuncture, collected into sterile vacutainers, and immediately placed on ice. For processing of plasma, the tubes were centrifuged at 1200 x g for 10 minutes at 4°C followed by a second centrifugation at 10,000 x g for 10 minutes at 4°C to generate platelet poor plasma. Plasma were then aliquoted and stored at -80°C until the samples were analyzed.

ELISA and multiplex analysis: BIMs were measured using the following ELISA kits: GFAP (Cat No: NS830, Sigma-Aldrich), NSE (Cat No: 420-85, IBL America), S100B (Cat No: EZHS100B-33K, MilliporeSigma), UCH-L1 (EH475RB, ThermoFisher), syndecan-1(RAB0736-1KT, MilliporeSigma) and MAP2 (EKU05950, BIOMATIK). The EIMs (including ICAM-1 and VCAM-1) were measured using a premixed multiplex assay (Cat. #HCVD2MAG-67K, MilliporeSigma). Systemic levels of CCs were measured using a 38-plex premixed immunological multiplex assay (HCYTMAG-60K-PX38, MilliporeSigma, Billerica, MA). CCs included CD40L, EGF, Eotaxin/CCL11, FGF-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Modified Rankin assessment: The functional status of the patient was quantified using the modified Rankin's scale (mRS) which is a 0-6 point grading scale of the patient's functional status 27 . '0': no deficits, '1': presence of symptoms but no significant disability, '2': a slight disability but independent, '3': moderate disability requiring some All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101/2021.05.25.21257353 doi: medRxiv preprint help but able to walk without assistance, '4': a moderately severe disability and unable to walk and attend to bodily needs without assistance, '5': a severe disability where the patient requires constant nursing care and attention and, '6': being dead. For the purposes of this study, we dichotomized patients into two groups; good (mRS≤3) and poor (mRS≥4) outcomes. The mRS at discharge was assessed by the attending neurointensivist taking care of the patient.

Patient characteristics: Samples from 57 subjects and 20 controls subjects were included in the study. Demographics and clinical outcomes of the COVID-19 subjects and controls are presented ( Table 1 ). There were no significant differences in age, sex and race distribution between the two groups. The COVID-19 cohort had a significantly more Hispanic subjects compared to the control (56% vs 10%, p<0.01). There were no differences in the history of hypertension, diabetes and coronary heart disease between the two groups. However, the COVID-19 group had more obese subjects compared to controls (49% vs 20%, p=0.03).

BIMs after COVID-19 hospitalization: At <48 hours of COVID-19 hospitalization, the mean levels of MAP2 (68 ± 7.5 vs 26 ± 3.9, pg/ml, p<0.01), NSE (16.9 ± 3.2 vs 4.9 ± 0.59, pg/ml, p<0.01) and S100B (113 ± 16 vs 43 ± 7, pg/ml, p<0.01) were significantly higher compared to controls ( Figure 1A ). In the COVID-19 cohort, the average levels of MAP2, NSE and S100B were 160%, 245% and 162% higher than controls. However, at 3 months after hospitalization, the levels of these markers were not significantly different from controls ( Figure 1A ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101/2021.05.25.21257353 doi: medRxiv preprint the EIMs and most CCs were significantly higher in the COVID-19 cohort compared to controls. EIMs including sICAM1 (317 ± 51 vs 108 ± 7.5, pg/ml, p<0.001) and sVCAM1 (637 ± 45 vs 390 ± 16, pg/ml, p<0.01) were significantly higher in COVID-19 compared to controls ( Figure 1B) . Of the 38 CCs investigated, 7 CCs were significantly higher and 2 CCs were significantly lower in COVID-19 ( Figure 1C ). The 7 CCs that were significantly higher were GRO (254 ± 29 vs 79 ± 5.19, pg/ml, p<0.01), IL10 (27 ± 5.7 vs 7.4 ± 2.5, pg/ml, p<0.01), sCD40L (144 ± 32 vs 40 ± 6, pg/ml, p<0.0001), IL1Ra(318 ± 131 vs 68 ± 28, pg/ml, p<0.01), IP10 (2952 ± 512 vs 148 ± 20, pg/ml, p<0.001), MCP1

(300 ± 34 vs 154 ± 8, pg/ml, p< 0.05) and TNFa (10 ± 0.5 vs 5± 0.4, pg/ml, p<0.01). The two CCs that were significantly lower in the COVID-19 cohort were MDC (158 ± 12 vs 231 ± 26, pg/ml, p<0.05) and MIP1a (2.5 ±0.4 vs 4.2 ± 0.8, pg/ml, p<0.05). At 3 months after COVID-19 hospitalization, the levels of BIMs and CCs (with the exception of MIP1a) were similar to the levels of the control cohort. We did not measure EIM levels at 3 months.

The association with inflammatory cytokines and COVID-19: Bioinformatics (Chord diagrams) analysis reveal distinct association profile between the COVID-19 and control cohort ( Figure 1D ). Within the COVID-19 cohort, we observed high positive correlations between the BIM and CCs indicative of a brain injury mechanism triggered by systemic inflammation. While IL6 levels were not significantly higher in the COVID-19 cohort, as previous studies have found they trended higher in men. In our cohort, we observed IL6 to highly correlated with other CCs and BIMs ( Figure 1D) . Several CCs and notably MCP1, IP10, IL6, IL1Ra, IL10 and TNFa had more associations (Figure 1D, COVID-19) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ;

with the BEM markers suggesting that these CCs are the inflammatory markers driving brain injury.

Severity and outcomes: We examined the levels of BIMs, EIMs and CCs across COVID-19 severity (mild, moderate and severe). The levels of BIM were not significantly different across severity. However, one EIM (sICAM1) and two CCs (SCD40L and IL1RA) were significantly higher in subjects with high severity (Figure 2A) . None of the BIMs or EIMs were predictive of functional outcomes at discharge. Two CCs, Eotaxin and MIP1b were significantly higher (p<0.05) in subjects who proceeded to have poor outcomes ( Figure 2B ). When adjusted for age and sex, only MIP1b was found to be independently associated with functional outcomes. MDC was significantly (p<0.05) lower in those who proceeded to have poor outcomes. However, when controlled for age and sex, it was not independently associated with outcomes ( Figure 2B ).

Sex Differences: Among the BIMs, only the levels of NSE was significantly higher in men compared to women (7.95 ± 0.9 vs 22.9 ± 5.8, p=0.01). BIMs including S100B, tau and MAP2 were higher in men; however, these differences were not statistically significant ( Figure 3A) . The levels of the EIMs were not significantly different across men and women (data not shown). Four CCs were significantly higher in men compared Figure 3B) . The BIM-EIM-CC interaction profile reveal stark differences between men than women ( Figure 3C ). Men had a higher number of correlations between the BIM-EIM-CC and the correlation profile was significantly All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; 1 0 different compared to women (p<0.05, Fisher's test). There were more interactions between the CCs and BIMs suggestive of a higher degree of inflammation induced brain injury in men. Additionally, in women, the EIMs (sICAM1 and SVCAM1) were not significantly correlated with the CCs or BIMs. However, in men, the EIMS were highly correlated with CCs and BIMs (Figure 3C ).

We investigated the profile of brain injury markers, endothelial injury and inflammatory markers after COVID-19 disease. We found that levels of BIMs, specifically MAP2, NSE and S100β were significantly elevated in the acute phase of COVID-19, with levels returning to normal at 3 months after hospitalization. We found that two EIMs, sICAM1 and sCAM-1, were elevated after COVID-19 infection with robust interactions with BIMs and IL6. Additionally, we identified a host of inflammatory markers that are elevated after acute COVID-19 infection and most return to normal at 3 months. Interestingly we found BIM in men were significantly higher than in women suggesting a strong sex dependent biological mechanism underlying the interactions between systemic inflammation, endothelial damage and brain injury after COVID-19.

The neuro-invasive and neurotropic nature of human coronaviruses (HCoV) are known, and they may contribute to both short-and long-term neurological disorders [9] [10] [11] .

The neuroinvasion of HCoVs confirmed by the presence of viral RNA in the human CNS adds credence to this hypothesis 28 . Acute neurologic and psychiatric complications have been reported after COVID-19 hospitalizations 2 . Neurologic manifestations have been reported in both the central nervous system and the peripheral nervous system. A wide range of neurological manifestations including ischemic stroke, intracerebral All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021.

hemorrhage, hallucinations, encephalopathy, anosmia and ageusia have been described after SARS-CoV-2 infection [3] [4] [5] [6] [7] [8] . Hyperemic and edematous brain tissue and neuronal death have been reported in autopsy cases after COVID-19 29 .

To investigate the effects of COVID-19 on BIMs, we examined systemic levels of six previously validated BIMs -MAP2, NSE, GFAP, S100B, Syndecan-1 and UCHL1.

We found that MAP2, NSE and S100B were higher after COVID-19 indicative of brain injury after COVID-19. MAP-2 is a dendritic injury marker and was found to be elevated in both the acute and chronic stages of brain injury 30 . It is a protein that is typically localized in the dendritic regions and is involved in the promotion of microtubule synthesis and cross-linking with other compartments of the cytoskeleton. It is elevated after a traumatic brain injury and was found to be associated with long-term outcomes 30 .

indicator of neuronal damage 31 . S100B is a calcium-binding protein that is localized in astrocytic cytoplasm. It has been shown to be elevated systemically especially in traumatic brain injuries 32 and strokes 33 . Systemic levels of S100B is higher after traumatic brain injury and have been associated with poor long-term outcomes [34] [35] [36] .

Increased levels of MAP2, NSE and S100B indicates neuronal and astrocytic injury after COVID-19 ( Figure 1A) . Additionally, we found that BIMs (NSE, S100β, tau, MAP2) were higher in men compared to women with COVID-19. It is not clear whether the elevations in BIMs overall and specifically in men have clinical relevance. We deliberately excluded samples from subjects with clear neurologic injury (i.e., traumatic brain injury, ischemic stroke, or hemorrhagic stroke) associated with COVID-19 disease. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The elevated BIMs suggest that there is CNS involvement in acute COVID-19 and the clinical ramifications need to be investigated urgently.

Several pro-inflammatory cytokines including IL10, MCP1, TNFa, MDC, GRO, sCD40L, IL1Ra and IP10 were higher after COVID-19 compared to controls confirming the findings of several studies that have reported an increased inflammatory response in COVID-19 37 . We also observed that EIMs (sICAM-1 and sVCAM-1) were higher after COVID-19 infection (Figure 1B) . Endothelial cells express the ACE-2 receptor -the primary receptor and main route in intracellular entry for SARS-CoV-2 38 .The blood-brain barrier (BBB) via the endothelial tight junctions is critical in maintaining cerebral homeostasis and the breakdown of BBB is implicated in variety of neurological diseases 39 . It has been shown that the BBB is compromised after COVID-19 and that the SARS-CoV-2 spike protein can cross the BBB into brain tissue 40, 41 . The endothelial dysfunction might be a direct result of the SARS-CoV-2 infection or due to a reaction to systemic inflammation triggered by the viral infection, or a combination of these factors.

TNFα 42 . It has been shown to promote leukocyte adhesion 43 and effects barrier function and vascular leak 44 . sICAM-1 is the circulating form of ICAM-1 and has been identified as a candidate marker of vascular inflammation 45 . Increased levels of sICAM-1 have been observed in cardiovascular disease including myocarditis 46 and inflammatory cardiomyopathy 47 . In addition to increased levels of sICAM-1, we found that TNFα was also elevated after COVID-19. In our data, the simultaneous elevation of the proinflammatory TNFα and sICAM-1 is suggestive of an inflammatory mediated vascular injury rather than a virally triggered vascular injury (Figure 1) . In fact, a recent NIH All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101/2021.05.25.21257353 doi: medRxiv preprint funded post-mortem study examining the brain tissue of deceased COVID-19 subjects reported extensive inflammation and microvascular blood vessel damage, but it is not clear how SARS-CoV-2 is involved in the brain injury and neurological outcome 48 . The findings of this study suggest that the microvascular blood vessel damage is likely caused by the inflammatory response due to the infection, rather than the virus itself.

To elucidate the relationships between the BIMs, EIMs and CCs,0 we employed a bioinformatics visualization tool called the chord diagram and overlaid the significant correlations. In the COVID-19 cohort, the CCs IL6, IL1Ra, IL10, TNFa, MCP1 and IP10 had high associations with MAP2, NSE and S100B. Among the BIMs, MAP2 and S100B had the most associations with the CCs (Figure 1D) . The relatively higher correlations between the BIMs and CCs in the COVID-19 cohort compared to controls suggest inflammation induced brain injury in COVID-19. It is known that inflammatory diseases are associated with neuronal injury (as in the case of encephalitis after sepsis 49 ).

Therefore, it is plausible that the extensive cytokine activation by COVID-19 infection is the primary inflammation driver and mediator of neuronal injury.

Interestingly, the levels of BIMs were not different across clinical severity or clinical outcomes. However, sICAM1 and two CCs (sCD40L and IL1Ra) were higher in severe grade subjects (Figure 2A) and three CCs (Eotaxin, MDC and MIP1b) were different across clinical outcomes (Figure 2B) . After adjusting for age and sex, only MIP1b was independently associated with clinical outcomes. The lack of differences in BIMs levels across severity or clinical outcomes could be a reflection of the time-point at which the samples were drawn rather than a pathophysiological mechanism of the disease process itself as we only analyzed the first sample that was available during All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; 1 4 hospitalization (obtained at <48 hours after admission) a time-period where typically the heterogeneity in clinical status is low.

The long-term neurological effects of COVID-19 are being increasingly recognized 50 . As more COVID-19 patients are recovering from hospitalization, it is expected that many discharged patients are afflicted with several secondary complications and symptoms 51 . These patients are referred to as "long-haulers" and they are reporting a host of medical symptoms that include functional, cognitive and psychiatric deficits [52] [53] [54] . We investigated whether brain injury and inflammation persists at 3-months after hospitalization and found that the systemic levels of BIMs (including MAP2, NSE and S100B) and most inflammatory CCs (except MIPI1a) were similar to the levels observed in controls indicating that there is no ongoing brain injury or higher inflammation at 3 months after COVID-19 hospitalization. It is likely that the neurological sequelae observed in the survivors are due to the consequence of the initial inflammatory cascade at the time of hospitalization rather than an ongoing process at 3 months.

COVID-19 disproportionately affects men more severely compared to women.

Preliminary studies have suggested that while the prevalence of infection is the same in men and women, men are more likely to be hospitalized and have a severe course of disease and higher mortality than women 15 . We investigated differences in BIMs and CCs across men and women and we found that NSE was significantly elevated in men compared to women. Additionally MAP2, tau and S100B showed trends towards elevated levels in men (Figure 3A) . Several CCs including IL15, IL8, MIP1b and IL10 were elevated in men compared to women (Figure 3B) suggesting an increased All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; 1 5 inflammatory response in men. Men had a higher degree of inflammatory interactions ( Figure 3C ) compared to women. Additionally, the interactions between the inflammatory markers (CCs) and the BIMs (red lines) were much dense in men indicating a higher degree of inflammation mediated brain injury in men during the acute stages of COVID-19 ( Figure 3C) . Interestingly, the interactions between the EIMs and the BIMs/CCs were also higher in men compared to women (Figure 3C ). This suggests that men likely experience a higher degree of inflammation triggered endotheliopathyan important factor to be considered when developing treatment plans. A number of reasons have been postulated for the differential response across sex to COVID-19.

Some studies have shown that men have a higher level of ACE2 receptors, used for SARS-CoV-2 virus entry 55 . Others have postulated that the differences are due to differences in lifestyle factors and co-morbidities between men and women 55, 56 . Given our small sample size, we are not powered to determine if these differences in BIMs translate into worse neurologic outcomes. Future studies investigating the differences in the sex profile across the sexes are required.

Limitations: Our study has a few limitations. First, we included samples only the first available time-point after hospitalization. Typically, the measurements from the firstavailable time point is a reflection of the patient's status during the earlier course of disease progress. However, this time-point is also the most accurate as in our hospital; all COVID-19 patients were administered dexamethasone, which could have a confounding effect on the measurements. Second, we have not related the observed BIMs with any long-term clinical outcomes. Third, we are underpowered to detect the effect of any co-morbidities on the neuronal injury. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ;

Our findings suggest that immediately after COVID-19 hospitalization, BIMs were higher than matched controls. The levels of EIMs and CCs were also higher. The CCs were highly correlated with BIMs and EIMs suggesting inflammatory-driven endothelial dysfunction and brain injury in the acute phase of COVID-19. Further studies are required to clarify the exact mechanisms how COVID-19 induces inflammation and brain injury, sex-specific differences and whether these early increase in injury markers are associated with long-term neurologic outcomes. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021. ; was significantly (p<0.05) higher after COVID-19. S100b, tau and MAP2 were higher but differences was not statistically significant (B) IL10, IL15, IL8 and MIP1a were significantly (p<0.05) in males compared to females. MIP1b, FGF2, GMCSF and IL6 indicated a non-significant trend of being elevated in males (C) The BIM-EM-CC interactions reveal that males have a much robust interactions compared to females.

There were no strong correlations between the EIMs and BIM/CCs in females. There were strong associations between EIM, CC and BIM in males. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. MAP2, NSE and S100B were significantly (p<0.05) higher immediately after CO months (B) sICAM1 was significantly higher and SVCAM1 was significantly low markers including GRO, IL10, sCD40L, IL1RA, IP10, MCP1 and TNFa were sig significantly lower after COVID-19. Except MIP1a, all CC markers returned to b lower at 3 months (D) Chord diagram reveals significant (p<0.05, Fishers' test across COVID-19 and control groups. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 27, 2021.

COVID-19. S100b, tau and MAP2 were higher but difference significantly (p<0.05) in males compared to females. MIP1b, elevated in males (C) The BIM-EM-CC interactions reveal th were no strong correlations between the EIMs and BIM/CCs in males. There were also strong interactions between EIMs A B COVID-19 subjects. (A) NSE was significantly (p<0.05) higher after nces was not statistically significant (B) IL10, IL15, IL8 and MIP1a were b, FGF2, GMCSF and IL6 indicated a non-significant trend of being l that males have a much robust interactions compared to females. There Cs in females. There were strong associations between EIM, CC and BIM s and TMPSS in males compares to females Women Men C All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Neurological associations of COVID-19

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients

Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?

Anosmia and Ageusia: Common Findings in COVID-19 Patients

Stroke as a Presenting Feature of Covid-19 in the Young | NEJM

Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Detection of Coronavirus in the Central Nervous System of a Child With Acute Disseminated Encephalomyelitis

Possible Central Nervous System Infection by SARS Coronavirus

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

Multiple organ infection and the pathogenesis of SARS

Impact of sex and gender on COVID-19 outcomes in Europe

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Considering how biological sex impacts immune responses and COVID-19 outcomes

S100B and its association with HIV-associated neurocognitive disorders

Evaluation of CSF Glial FibrillaryAcidic Protein (GFAP) as a Putative Marker for HIV-AssociatedDementia

Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV

Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia

Elevated Serum Glial Fibrillary Acidic Protein (GFAP) is Associated with Poor Functional Outcome After Cardiopulmonary Resuscitation

Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients

The dynamic change of serum S100B levels from day 1 to day 3 is more associated with sepsis-associated encephalopathy

Modified Rankin Score (mRS)

circlize implements and enhances circular visualization in R

Neuroinvasion by Human Respiratory Coronaviruses

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury

Utility of neuron-specific enolase in traumatic brain injury

relations to S100B levels, outcome, and extracranial injury severity

A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury

Release of Glial Tissue-Specific Proteins After Acute Stroke

S100b as a Prognostic Biomarker in Outcome Prediction for Patients with Severe Traumatic Brain Injury

Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis

S100B is an important outcome predictor in traumatic brain injury

The trinity of COVID-19: immunity, inflammation and intervention

The ACE-2 in COVID-19: Foe or Friend?

The blood-brain barrier in brain homeostasis and neurological diseases

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier

The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice

Induction of ICAM-1 by TNF-alpha, IL-1 beta, and LPS in human endothelial cells after downregulation of PKC

Intercellular Adhesion Molecule 1 (ICAM-1): Getting a Grip on Leukocyte Adhesion

Expression Causes Endothelial Cell Leakiness, Cytoskeletal Reorganization and Junctional Alterations

Soluble ICAM-1: a marker of vascular inflammation and lifestyle

Expression of intercellular adhesion molecule-1 on cardiac myocytes for myocarditis before and during immunosuppressive therapy

sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy

NIH study uncovers blood vessel damage and inflammation in COVID-19 patients' brains but no infection

Sepsis-associated encephalopathy: a vicious cycle of immunosuppression

NIH launches new initiative to study "Long COVID

Long-term consequences of COVID-19: research needs. The Lancet Infectious Diseases

Long Covid: quantitative and qualitative analyses of online Long Haulers' experiences, emotions and practices in the UK

Why Men are More Vulnerable to Covid-19 Than Women?

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

The authors thank all the health care workers and the research personnel who tirelessly cared for the worked were involved in the care and the follow-up of the patients. This work was partly supported by an award from the Huffington Foundation to Dr. Louise D.McCullough. We thank The Biorepository of Neurological Diseases team for their efforts in collecting the samples.